Vaxcyte, Inc. — Director's Dealing 2020

Jun 12, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2020-06-11

Reporting Person: Longitude Capital Partners II, LLC (10% Owner)
Reporting Person: Longitude Venture Partners II, L.P. (10% Owner)
Reporting Person: ENRIGHT PATRICK G (10% Owner)
Reporting Person: Tammenoms Bakker Juliet (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Common Stock (1912237)		Indirect
Series B Preferred Stock	$		Common Stock (1064940)		Indirect
Series C Preferred Stock	$		Common Stock (397960)		Indirect
Series D Preferred Stock	$		Common Stock (231213)		Indirect

Footnotes

F1: The Series A Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series A Preferred Stock will be converted into shares of Common Stock for no consideration.

F2: The securities are held of record by Longitude Venture Partners II, L.P. ("Longitude II"). Longitude Capital Partners II, LLC, ("LCP2"), the general partner of Longitude II, may be deemed to have voting, investment and dispositive power with respect to the shares held by Longitude II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP2 and may be deemed to have voting, investment and dispositive power over the shares held by Longitude II. Each of LCP2, Mr. Enright and Ms. Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.

F3: The Series B Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series B Preferred Stock will be converted into shares of Common Stock for no consideration.

F4: The Series C Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series C Preferred Stock will be converted into shares of Common Stock for no consideration.

F5: The Series D Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series D Preferred Stock will be converted into shares of Common Stock for no consideration.